Live
Funding 2 min read

Norwegian startup secures $7 million to scale technology for studying living human tissue

Trondheim-based biotech company Vitroscope has raised $7 million through a financing package that includes a $5 million seed round and $2 million in non-dilutive funding. The funding will support the commercial rollout of their tissue study technology.

Image: ArcticStartup

Vitroscope, a biotech company based in Trondheim, has successfully raised $7 million to advance its technology for studying living human tissue. This financing package consists of a $5 million seed round led by Cerberus Ventures and YZR Capital, alongside $2 million received from the Research Council of Norway.

Specializing in automated perfusion platforms, Vitroscope offers solutions that maintain living tissue under controlled conditions, thereby enabling researchers to explore immune activity and disease mechanisms over time. The newly acquired funds will be directed towards the commercial rollout of its vitro.alive benchtop platform and the validation of a higher-throughput system called vitro.scale.

With this funding, Vitroscope aims to enhance lab capabilities for drug discovery and translational research, ultimately addressing limitations evident in traditional cell culture methods.

Reporting sources

Where this story comes from

1 reference

The facts above are grounded in the original reporting linked here. Open the publisher story for its complete context.

ArcticStartup Open source

Norwegian startup secures $7 million to scale technology for studying living human tissue

The available publisher preview does not add detail beyond this brief. Open the original report for its full context.

Related coverage

This story in context

Read the closer connections in publication order. Separate background links appear below.

Earlier coverage 1

  1. Same event

    Vitroscope raises USD 5 million in funding

    The review connects these reports to the same identifiable event. The source excerpts show the basis for the connection.

    Shifter
    Why linked? View evidence
    Norwegian startup secures $7 million to scale technology for studying living human tissueRecorded source excerpt · original wording
    Trondheim-based biotech company Vitroscope has raised $7 million in a financing package comprising a $5 million seed round co-led by Cerberus Ventures and YZR Capital , alongside $2 million in non-dilutive funding from the Research Council of Norway . Arcas Ventures , Golden Egg Check , Devico Invest and angel investors Carles Reina , Fàtima Godall and Oskari Pétas also participated in the seed round .
    ArcticStartup ↗
    Vitroscope raises USD 5 million in fundingRecorded source excerpt · original wording
    Trondheim-baserte Vitroscope henter 5 millioner dollar i en såkornrunde ledet av Cerberus Ventures og YZR Capital. Kapitalen skal kommersialisere laboratorieplattformen for forskning på levende menneskevev. Ventureavdelingen til amerikanske Cerberus og europeiske YZR Capital leder såkornrunden i Trondheim-selskapet,...
    Shifter ↗
You are reading this story
About this history review

The link graph’s cryptographic signature was verified. This proves integrity, not the truth of every claim or complete archive coverage.

Graph updated . Only articles retained in the public archive are included.

Open technical link data
Method & transparencyHow this brief was selected and checked
Editorial priority6 / 10

Tracked

Source coverageSingle-source report

Single-source report

ConfidenceLimited

43 / 100 · one source

Source basis

Grounded in the publisher material listed below.

Confirmation

No second independent source has been matched to this story yet.

Selection

Selected for publication after relevance, freshness and editorial-quality checks.

Selection factors

  • 1 independent source
  • 1 concrete event indicator
  • editorial priority

Source monitoring: 89% recent availability · No source-health warnings. The original publisher remains the authoritative source for the full report.